Helix BioMedix Completes Clinical Studies of SmartPeptides(TM) Products

"Our SmartPeptides technology found in Striking Skin Care products performed well in clinical evaluation with high consumer appeal," said Dr. Tim Falla, Chief Scientific Officer at Helix BioMedix. "We are delighted with the results of these third-party studies documenting the benefits of SmartPeptides technology for people seeking improved skin texture and hydration. We plan to present the studies at upcoming dermatology conferences, while we wait for publication of the complete study."

The Company is in the process of submitting study synopsis articles for publication in leading peer reviewed journals.

All three studies were conducted by Essex Testing Clinic, Inc (Verona, NJ) over an eight week period with evaluations at baseline, eight hours and at two, four and eight weeks. Evaluations consisted of physician and patient assessments as well as measurements of skin hydration, topography and texture using Corneometer(R), Visia CR(R) and ImagePro(R) instrumentation.

Summary findings of the studies are as follows:

SERUM: In a 32 person study (average age 54) the Striking Skin Care serum produced a statistical improvement in vertical forehead lines with 74% of subjects showing improvement. A statistical improvement was also seen in skin texture with 87% of subjects showing improvement. Reductions in forehead wrinkles could be seen as early as two weeks in certain individuals.

EYE: A 30 person study (average age 52) documented a statistical reduction in the appearance of crow's feet was seen with 97% of subjects showing improvement. From the earliest time point of 8 hours, subjects exhibited a statistical improvement in skin texture and moisturization with 100% and 83% showing improvement respectively.

MOISTURIZER: In a 30 person study (average age 51) the Striking Skin Care moisturizer produced a statistical improvement in skin hydration at all time points from 8 hours through 8 weeks with 87% of participants showing improvement. Statistical improvement in skin texture was also seen with 87% of people showing an improvement; in certain individuals this was apparent after only two weeks.

No irritation or adverse effects were reported throughout these third party studies or in repeat patch test insult studies run in parallel. In all studies statistical significance was taken as p less-than or equal to 0.005.

About Heptapetide-7

Heptapeptide-7 is the latest advance in peptide technology from Helix BioMedix. This bioactive peptide has been shown in vitro to promote keratinocyte proliferation and migration, to support skin renewal, and to stimulate the production of collagen strengthening skin structure. A SmartPeptides technology, Heptapeptide-7 helps restore tone and firmness of perimenopausal and menopausal hormonally challenged skin while decreasing the appearance of fine lines and wrinkles.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking, SmartPeptides and HB-Aminobright are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

SOURCE: Helix BioMedix, Inc.

Investor Contact: 
Shelton Group Investor Relations 
Matt Kreps, 972-239-5119 X 125 
mkreps@sheltongroup.com 
or 
Company Contact: 
Helix BioMedix, Inc. 
R. Stephen Beatty, 425-402-8400 
President and CEO 
sbeatty@helixbiomedix.com